Category Archives: PRNews

PRNews

Merck Opens its First Customer Food Safety Studio

– New Food Safety Studio in Bellevue, Washington, serves as global center for innovation and collaboration

– Demonstration and training lab space extends product and process development to customers

DARMSTADT, Germany, Aug. 30, 2017 /PRNewswire/ — Merck, a leading science and technology company, has opened its first global Food Safety Studio in Bellevue, Washington for manufacturers of all types of food (beef, poultry, produce, etc.) to collaborate with Merck scientists on developing safety products for rapid detection of foodborne pathogens.

The new 5,300-square foot center gives customers access to a complete food safety workflow, from raw materials testing to finished-product safety testing, to help find, correct and prevent hazards within the food supply chain. The center allows customers to work with many manual or automated food safety products such as testing kits and hygiene swabs that are critical to maintaining safety throughout the manufacturing process.

“The opening of Merck’s Food Safety Studio demonstrates our commitment to ensuring the safety of the global food supply,” said Jean-Charles Wirth, Head of the Applied Solutions business unit, Life Science at Merck. “We are bringing teams together in a workspace designed to foster open innovation and collaboration with the goal of becoming the leader in food safety testing.”

According to the World Health Organization, an estimated 600 million people in the world — almost one-in-10 — fall ill after eating contaminated food, and 420,000 die every year.

Merck, which earlier this year acquired BioControl Systems, a global leader in food safety testing, helps customers protect the global food supply by providing a comprehensive portfolio of state-of-the-art testing technologies.

Customer visits are being scheduled for the new Food Safety Studio, which features a Food Safety Demonstration Center designed with a classroom setting and demonstration lab.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Merck Collaborates with Angiex to Speed Clinical Readiness of New Cancer Therapy

– Project is first for Merck’s Massachusetts BioReliance® End-to-End Solutions center

– Collaboration gives Angiex access to Merck’s process development tools and technologies

DARMSTADT, Germany, Aug. 29, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up’s ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody-drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.

The collaboration with Angiex is the first project to be undertaken at Merck’s new biodevelopment center in Massachusetts, USA. Merck will give Angiex access to end-to-end process development tools, education programs and training to support its success.

“Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer for companies like Angiex.”

Angiex CEO Dr. Paul Jaminet applauded Merck’s broad range of process development capabilities and services for customers at all stages of molecule development and commercialization. “Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate Merck’s expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors,” Jaminet said.

Merck’s BioReliance® End-to-End Solutions deliver products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance® End-to-End Solutions, Merck will inaugurate its new biodevelopment center in Burlington, Massachusetts in October 2017.

Merck’s BioReliance® End-to-End Solutions is part of the Process Solutions business area within the Life Science business of Merck.

About Angiex
Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex’s lead product is an antibody-drug conjugate therapy for cancer. Angiex is resident at LabCentral in Cambridge, Massachusetts.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Ganeden Brings Probiotic Exhibit and Expertise to Fi Asia

Global leader will discuss probiotic formulation trends, science updates and product launches

CLEVELAND, Aug. 29, 2017 /PRNewswire/ — As probiotic fortification continues to gain momentum around the world, probiotic leader Ganeden is expanding its presence at additional food and beverage events globally—including in Asia. This September, experts from the top probiotic ingredient supplier will be attending Food Ingredients Asia (Fi Asia) in Bangkok. Team members based locally and from the U.S. headquarters will be on site to discuss new probiotic research, offer insight into upcoming product launches and help manufacturers explore innovative probiotic formulations beyond traditional dairy applications.

Ganeden has become a driving force in the probiotic space internationally, helping hundreds of manufacturers use probiotic technology in their products in innovative ways—including many in Asia. As a global leader, the science-driven company is knowledgeable on probiotic trends around the world, including consumer demand, research advancements and innovative options for probiotic fortification beyond the dairy case. Experts can assist in probiotic ingredient selection, including providing details on strain specificity, study requirements and health benefits.

“There are tremendous growth opportunities for probiotic technologies in the Asian market, and Fi Asia gives us a chance to provide expertise on how health benefits can be added to products to drive consumer interest and purchases,” said Stephen Quinn, business and regulatory director for Asia at Ganeden. “We plan to meet with industry leaders and innovators to demonstrate how functional ingredients can benefit end-users and grow business. There is a strong tradition of probiotics in Asia, but nearly all of it is in the supplement and dairy categories, so having a chance to provide the same health benefits in other food and beverage applications is exciting for manufacturers and their customers.”

Ganeden is best known for GanedenBC30® (Bacillus coagulans GBI-30, 6086), its patented and shelf stable probiotic ingredient that remains viable through most manufacturing processes, shelf life and gastric transit—allowing it to be fortified into almost any food or beverage product. Years of ongoing studies confirm the strain’s safety, digestive and immune support, and protein utilization benefits. And because GanedenBC30 has been shown to survive 10X more effectively than yogurt cultures, it has become one of the top ingredient choices for probiotic benefits in both refrigerated and non-refrigerated products.

During the show, Ganeden will also introduce the newest addition to its ingredient portfolio—Staimune™. The new ingredient uses the inactivated cells of GanedenBC30, which have been shown to support immune health. Staimune’s ease of formulation opens up new opportunities in immune-focused, functional foods and beverages which involve processes too harsh for live probiotics.

To meet with probiotic experts at the Fi Asia show, contact Ganeden or visit booth #F34. For more information on the probiotic company, including its ingredient portfolio, research and international presence, visit GandedenProbiotics.com.

About Ganeden:

Ganeden® is at the forefront of probiotic research and product development with an extensive library of published studies and more than 135 patents for probiotic technologies in the supplement, food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30®, its patented, FDA GRAS, highly stable probiotic ingredient. Through the fermentation process of GanedenBC30, Ganeden developed Bonicel®, the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. Ganeden’s newest ingredient, Staimune™ is a patented probiotic technology comprising of inactivated GanedenBC30 which has been shown to have immune benefits. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com. 

PRNews

Tekni-Plex begins production at new China manufacturing facility

$15 million investment supports Tekni-Plex’s continued commitment to global supply network

WAYNE, Pennsylvania, Aug. 28, 2017 /PRNewswire/ — Tekni-Plex, Inc.’s new state-of-the-art manufacturing facility in Suzhou, China, near Shanghai has begun production. The company will hold a grand opening celebration on September 19th.


Tekni-Plex, Inc.’s new state-of-the-art manufacturing facility in Suzhou, China, near Shanghai has begun production. The company will hold a grand opening celebration on September 19th. The facility is producing Natvar’s recently-announced silicone extrusion tubing and Colorite custom compounds for medical device applications. Production will also include Action Technology’s dip tubes for food/beverage, pharmaceutical, personal care, industrial and household pump products.

Earlier this year, Tekni-Plex announced a $15 million investment in the facility to support the growing needs of the Asia-Pacific pharmaceutical and medical device market.

The more than 140,000-square-foot (13,000-square-meter) facility has already started manufacturing products for Tekni-Plex’s Natvar, Colorite and Action Technology business units. The facility features three Class 100K cleanrooms to accommodate medical-grade tubing and components production plus one Class 10K cleanroom that will produce Natvar’s pharma-grade tubing.

The facility is producing Natvar’s recently-announced silicone extrusion tubing for catheters, feeding tubes, drug delivery and peristaltic pump applications. Production for microextrusion tubing that targets a wide variety of demanding neurovascular interventional therapies and surgical applications is expected to be onstream early next year. The facility will also manufacture Colorite custom compounds for medical device applications, and Action Technology’s dip tubes used in a wide variety of food/beverage, pharmaceutical, personal care, industrial and household pump applications.

Among those representing Tekni-Plex at the ribbon cutting will be Paul Young, chief executive officer, Russell Hubbard, vice president-international and general manager, Ian Kenny, global managing director, Colorite, and Bob Donohue, general manager of the company’s Natvar business unit.  Local officials are also expected to attend.

For further information about attending the event contact Coco Xu at Coco.Xu@tekni-plex.com.

About Tekni-Plex, Inc.
Celebrating its 50th anniversary in 2017, Tekni-Plex is a globally-integrated company focused on developing and manufacturing innovative packaging materials, medical compounds and precision-crafted medical tubing solutions for some of the most well-known names in the medical, pharmaceutical, personal care, household and industrial, and food and beverage industries. Tekni-Plex is headquartered in Wayne, Pennsylvania, and operates manufacturing sites across eight countries worldwide to meet the needs of its global customers.  For more information visit www.tekni-plex.com.

Logo – http://mma.prnewswire.com/media/177084/tekni_plex_logo.jpg

Source: Tekni-Plex, Inc.

PRNews

Merck to Acquire Natrix Separations to Advance Next-Generation Processing Capabilities

— Boosts Merck’s single-use chromatography portfolio

— Accelerates Merck’s mAb and vaccine manufacturing offering

DARMSTADT, Germany, Aug. 28, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced that it has entered into an agreement to acquire Natrix Separations, an Ontario, Canada-based provider of hydrogel membrane products for single-use chromatography. The transaction is expected to close in Q3 of 2017. Financial details were not disclosed.


Merck signed an agreement to acquire Natrix Separations, a company known for its technology platform capable of delivering high productivity and impurity removal in a single-use format. This acquisition complements Merck’s efforts to drive next-generation bioprocessing, ultimately enabling faster, more efficient technology for customers. Pictured here is a magnified view of the Natrix HD Membrane pore structure, comprised of up to 95 percent functional monomer.

Natrix is known for its unique technology platform capable of delivering high productivity and impurity removal in a single-use format, an ideal fit with next-generation processing. This acquisition complements Merck’s efforts to drive next-generation bioprocessing, ultimately enabling faster, more efficient technology for its customers.

“The Natrix technology platform, and the development options and capabilities that this brings for single-use and rapid cycling chromatography, will allow us to accelerate our offering in mAb and vaccine manufacturing,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “This acquisition creates tremendous opportunity to drive growth and advancement in next-generation processing—an area of increasing importance to our customers.”

Next-generation processing is any technology, expendable or system that changes the existing monoclonal antibody manufacturing template through unit operation intensification, connection of unit operations, or fully continuous processing. Biomanufacturers are moving toward next-generation processing because of its many benefits, including increased plant productivity, facility flexibility, cost efficiencies and reduced risk. Next-generation processing is expected to triple in market size between 2020 and 2025.

Natrix markets both an anion exchange membrane and cation exchange membrane. Natrix is developing additional products to enable a fully single-use, full-scale biological purification process.

“Joining Merck gives us the opportunity to collaborate with some of the best minds in the industry, allowing us to further the great work done by our scientists,” says John Chickosky, CEO, Natrix Separations. “I am truly excited to become part of a larger effort and see the benefits of this combination in the advances we will make for our customers and the global scientific community.”

About Natrix Separations, Inc.
 Natrix Separations enables fast and flexible manufacturing of biopharmaceuticals through high-productivity disposable downstream processing products. The innovative Natrix HD Membranes overcome the limitations in efficiency, speed, and flexibility imposed by conventional capital-intensive approaches to chromatography. Natrix products feature well-established industry-standard chemistries, and are scalable from R&D to commercial manufacturing. Natrix is headquartered in Burlington, Ontario, Canada. For additional information, visit www.natrixseparations.com

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
 Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.
Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Photo – https://mma.prnewswire.com/media/548923/Merck_Acquires_Natrix_Separations.jpg

PRNews

Why do hair loss prevention and treatment industries pay attention to P1P, a cell-regenerating substance developed in Korea?

-Its effectiveness in overcoming and preventing stress hair loss comes into light

ANYANG, South Korea, Aug. 24, 2017 /PRNewswire/ — P1P (Phytosphingosine 1 Phosphate), a cell-regenerating substance developed in Korea, which is thought to be effective in overcoming hair loss caused by stress, is now drawing attention from the domestic hair loss prevention and treatment industry.


Dr. Myung-Joon Choi of KAIST who released P1P

It was learned that ‘S1P(Sphingosine 1 Phosphate),’ a substance found minimally in the blood, helps to regenerate cells in the body and prevent aging, is effective in preventing necrocytosis due to stress. However, the idea did not lead to the development of products owing to expensive prices.

Under such circumstances, a team of doctors at KAIST continued to delve into the matter in search of its analogs, and succeeded in identifying P1P. By applying P1P to cosmetic and hair loss prevention products, ‘P1P’, a ‘phytosia’ and aesthetic skin care brand, was launched into the market, earning a patent associated with prevention and treatment of hair loss, and a composition for hair growth. From this connection, a skin and hair society in Europe announced the effect of P1P on the mechanism of hair growth.

Dr. Myung-Joon Choi of KAIST who released P1P said, “While studies are actively under way on the application of P1P worldwide, the projects have met a limitation, that is, it is prohibitively expensive, making it a project of low marketability. Under such circumstances, I am so glad that we managed to open the possibility of commercializing the substance since we have secured a technology of synthesizing the substance for mass production. We will continue to work steadily on the project to introduce better products.” 

The P1P substance developed by Korea’s phyto-associated industries are expected to find extensive applications in the domestic medical and bio-industry for stem cell culture technology and the treatment of degenerative neurological diseases.

Contacts:

PHYTOS Co., Ltd.
Myeongjun Choi
Mobile: +82)10-9369-5339
Office: +82)70-7404-6642
Email: myeongjun@p1p.kr

View original content with multimedia:http://www.prnewswire.com/news-releases/why-do-hair-loss-prevention-and-treatment-industries-pay-attention-to-p1p-a-cell-regenerating-substance-developed-in-korea-300509167.html

PRNews

Young Living Essential Oils Promotes Lauren Walker to Chief Supply Officer

-Walker Leads the Sourcing Pillar of Young Living’s Seed to Seal Program-

LEHI, Utah, Aug. 18, 2017 /PRNewswire/ — Young Living Essential Oils, the world leader in essential oils, today announced that it has promoted Lauren Walker to the role of Chief Supply Officer. In her time with Young Living, she and her team have further implemented rigorous sourcing standards while also streamlining manufacturing, warehousing and fulfillment operations.

“Lauren embraces Young Living’s passion for being stewards of the earth and has been a driving force in ensuring that the sourcing, manufacturing and shipping components of our business all operate under that mindset,” said Jared Turner, Young Living Chief Operating Officer. “Her experience and expertise in project management, manufacturing, and supply chain gained throughout her career has been a great addition to our strong executive team.”

Walker leads the sourcing pillar of Young Living’s Seed to Seal program (Sourcing, Science and Standards), that governs how we obtain our products — whether from our corporate-owned farms, partner farms, or Seed to Seal-certified supplier. The sourcing pillar is also a major part of how we verify, through internal and third-party tracking, that the superior essential oils and premium ingredients in our products such as foods, skin care, and supplements were produced and manufactured according to industry best practices and our own high standards.

“We have an obligation to provide our customers with the highest quality products and the best customer experience, and we do that by having effective processes in place,” said Walker. “I’m proud that our team has assessed the whole supply chain of an oil and refined or established processes that help us provide the best products and services to our customers.”                   

Throughout her three-decade career with high-profile international companies, Walker has established herself as a leader and an innovator in streamlining global systems. After completing her engineering degree, she worked for Xerox as an engineer, followed by 10 years with Procter & Gamble in supply chain, manufacturing/technical operations, and quality. She also worked for seven years with Johnson & Johnson as a plant manager and as Program Manager of their Oral Care franchise. Prior to joining Young Living in 2016, she was Vice President of Manufacturing at Amway, where she was responsible for manufacturing across all product lines: nutrition, home care, personal care, beauty care, durable goods, and paper products.

In addition to her extensive experience, Walker has been a keynote speaker for American Manufacturing Strategies Summit and Front End Innovations Conference, is a Lean Six Sigma Project Champion in Manufacturing, and is Green Belt Certified. She holds a degree in engineering from Union College in New York. Lauren currently serves on the Board of Directors for the Salt Lake Chamber.

About Young Living Essential Oils
Young Living Essential Oils, LC, is the world leader in essential oils, with a strict Seed to Seal® process that produces pure essential oil products for every individual, family, and lifestyle. This process ensures that all products are genuine, free of synthetic chemicals, and pure. This commitment stems from the company’s more than 20 years of stewardship toward the earth and its people. For more information, visit YoungLiving.com.

Media Contact:
For media inquiries, please contact prinquiries@youngliving.com.

Photo – https://mma.prnewswire.com/media/546503/Lauren_Walker_Young_Living_Essential_Oils.jpg
Logo – https://mma.prnewswire.com/media/323110/Young_Living_Essential_Oils_Logo.jpg

PRNews

OpenEye Announces Pfizer To Adopt Orion Cloud Platform For Computational Chemistry

SANTA FE, New Mexico, Aug. 17, 2017 /PRNewswire/ — OpenEye Scientific Software, Inc., an innovative developer of molecular modeling and cheminformatics solutions, today announced that it has entered into an agreement with Pfizer Inc., to provide Orion, OpenEye’s new cloud platform, to the company’s Medicinal Sciences division.  Orion will equip chemists with all of OpenEye’s software, extensive tools for data visualization and communication, useful data sources and customizable, task-oriented workflows, all in a robust, scalable, cloud environment.

“We believe that Orion has the potential to revolutionize how computation is delivered to the pharmaceutical industry,” said Dr. Anthony Nicholls, CEO and founder of OpenEye Scientific Software, Inc. “Orion marries the immense resource of cloud computing services, with our insights, science and tools from two decades of helping customers. It continues and expands our tradition of computing at scale, reliable, predictive science and facilitating local innovation. As an open, collaborative platform for both industry and academia we think it can enhance the drug discovery process.”

“We look forward to implementing Orion’s workflow tools to help our efforts to deliver potential breakthrough therapies for patients,” said Enoch Huang, Executive Director of Computational Sciences at Pfizer.

About OpenEye

OpenEye has built a reputation as a scientific leader in the field of molecular design based on two decades of delivering useful applications and programming toolkits. Our scientific approach has focused on the power of molecular 3D structure to inform and guide, in particular via the concept of shape similarity. We have changed industry perception of what is possible with the speed, robustness and scalability of our tools and have recently built these into a ground-up, cloud-native platform, Orion. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization. OpenEye Scientific is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts, Cologne, Germany, Strasbourg, France and Tokyo, Japan.  For further information on the company and its products, see www.eyesopen.com.

FOR ADDITIONAL INFORMATION

OPENEYE SCIENTIFIC SOFTWARE, INC.

Jeffrey Grandy, Vice President, Sales

+1 505-473-7385 x60

Email: sales@eyesopen.com

PRNews

Decision Resources Group Acquires Context Matters to Expand Global Market Access Intelligence Offerings

BURLINGTON, Massachusetts, Aug. 16, 2017 /PRNewswire/ — Decision Resources Group (DRG), the life sciences industry’s most trusted provider of market intelligence and global data products and services, today announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform. Previously the lead investor in a Series B funding round for the startup last fall, DRG’s full acquisition and planned integration of Context Matters cements its position as the partner of choice for global market access data products, analytics, and strategic guidance.

The acquisition of Context Matters reinforces DRG’s commitment to providing a deep understanding of global market access landscapes which life sciences organizations can leverage to drive profitable asset management from development through commercialization. It will fortify DRG’s global market access portfolio by combining the novel Context Matters data model, which links global regulatory and health technology assessment data to detailed clinical trial data, with DRG’s existing suite of products and services.  The addition of Context Matters will result in a full service global market access and drug value navigation partner to the life sciences industry, with the flexibility to deliver solutions scaled to client needs and timing—from tactical target points to end-to-end enterprise strategy.

“There is an ever-rising demand to optimize global access to treatments for patients in therapy areas that continue to have unmet need. In our increasingly complex and cost-benefit driven markets, it is imperative for healthcare companies to build robust, evidence-based approaches to plan and prepare their assets for successful global market access,” says Peter Hempshall, Senior Vice President of DRG. “With the acquisition of Context Matters, DRG is pleased to welcome an experienced team of pioneering global market access experts. They have been at the forefront of compiling and connecting disparate forms of data to provide life sciences companies with the depth of data and direction needed to plan and implement successful access, reimbursement and asset valuation strategies for varied global markets.”

“Context Matters was created from the idea that data from market access and reimbursement can be used to inform clinical trial design,” explained Yin Ho, M.D., M.B.A., the Founder and CEO of Context Matters. “It has been extremely gratifying to watch Context Matters become a force to change the thinking of the pharmaceutical industry around how to use data to position and honestly evaluate the value of customers’ assets in a global marketplace,” said Dr. Ho. “We have been leaders in the industry and our vision will continue to live on in our products, services, and customers as we move forward with DRG.”

About Context Matters, Inc.

Context Matters modernizes and improves the process of valuing drug therapies, empowering life sciences organizations to achieve optimal reimbursement for their innovation. The Context Matters Market Access Platform (MAP) defines a new product category for global drug valuation — a configurable technology platform linking drug development and market data through a sophisticated model making comparative analysis and contextual views possible to establish reimbursement and market access. The MAP is a disruptive innovation that provides pharmaceutical and biotechnology companies direct access to the insights they need to inform key product development decisions and gain optimal reimbursement value. Visit ContextMatters.com for more information.

About Decision Resources Group

Decision Resources Group, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the development and delivery of life-changing therapies rely on DRG’s in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets. Please visit decisionresourcesgroup.com for more information.

For press inquiries, please contact Tori Gillern at tgillern@teamdrg.com.

PRNews

Crowdfunding Success of OYO Fitness’s DoubleFlex Gym Spreads Globally

KANSAS CITY, Miss., Aug. 16, 2017 /PRNewswire/ — After becoming the second highest funded Kickstarter fitness product in history, Kansas City-based OYO Fitness has now launched their DoubleFlex Black Portable Gym on the Backer Founder crowdfunding site in Taiwan. The company’s foray into overseas markets will be followed by additional crowd funding launches on other global sites next month. This personal gym features patented SpiraFlex technology which provides the same benefits as weight training. SpiraFlex has been used by NASA astronauts on the International Space Station and in the Bowflex Revolution home gym.


A crowdfunding effort for the DoubleFlex Black Portable Gym is now underway in Taiwan.

OYO Fitness has received over $700,000 in orders from backers on Kickstarter, placing it in the top 99.9 percent of all products ever offered on this leading crowdfunding site. Since then, OYO has gone on to raise an additional $226,000 through crowdfunding site Indiegogo, bringing total crowdfunding orders to over $930,000 so far.

On the Taiwanese Backer Founder site, the DoubleFlex Black is available at a pre-order price in two configurations that provide 15 or 25 pounds of resistance and include leg and door attachments for a total body workout. Over 75 exercises can be performed in the comfort of the home, office or on the go.  

“Following our success on Kickstarter and Indiegogo, we are thrilled to bring the DoubleFlex Black to other global crowdfunding sites at a discounted price before general distribution to consumers and health clubs in December,” said OYO Fitness founder and CEO Paul Francis. “The overwhelming response speaks directly to consumers’ desire for a fitness product that is both efficient and portable, and that can be used anywhere amid today’s busy lives.” The DoubleFlex Black is available for pre-order in Taiwan at: https://www.oyofitness.com.tw

For US and other countries, the DoubleFlex Black is available for pre-order at:
https://igg.me/at/oyo/x/16092817

The closed Kickstarter campaign can be seen at:
http://kck.st/2lmsXZN

Please visit our website at oyofitness.com and Facebook.com/oyofitness to learn more about OYO Fitness and their products that fits fitness into busy lifestyles.

Photo – http://mma.prnewswire.com/media/544925/OYO_Fitness_DoubleFlex_Black.jpg